Pages that link to "Q38485006"
Jump to navigation
Jump to search
The following pages link to Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. (Q38485006):
Displaying 50 items.
- Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster (Q24670351) (← links)
- C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer (Q24795406) (← links)
- Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing (Q24797752) (← links)
- Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry (Q24797806) (← links)
- HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells (Q25257668) (← links)
- Computer-assisted assessment of the human epidermal growth factor receptor 2 immunohistochemical assay in imaged histologic sections using a membrane isolation algorithm and quantitative analysis of positive controls (Q30482618) (← links)
- Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials. (Q33661325) (← links)
- Immunohistochemistry as an important tool in biomarkers detection and clinical practice (Q33704442) (← links)
- Utilization of HER2 genetic testing in a multi-institutional observational study (Q33771243) (← links)
- Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy. (Q33801908) (← links)
- Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives (Q33807542) (← links)
- ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression (Q33829405) (← links)
- Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer (Q33890758) (← links)
- ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency (Q33963261) (← links)
- Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study (Q34129444) (← links)
- ErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis (Q34133760) (← links)
- Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications (Q34223494) (← links)
- Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients (Q34344146) (← links)
- Testing for HER2 in Breast Cancer: A Continuing Evolution (Q34424285) (← links)
- HER2 overexpressing metastatic breast cancer (Q34677844) (← links)
- Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer (Q35038093) (← links)
- Estrogen receptor-negative breast ductal carcinoma: clinicopathological features and MIB-1 (Ki-67) proliferative index association (Q35106790) (← links)
- The Potential Utility of Curcumin in the Treatment of HER-2-Overexpressed Breast Cancer: An In Vitro and In Vivo Comparison Study with Herceptin (Q35184360) (← links)
- T lymphocyte density and distribution in human colorectal mucosa, and inefficiency of current cell isolation protocols (Q35344900) (← links)
- Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET (Q35350578) (← links)
- Immunohistochemical study of the expression of MUC5AC and MUC6 in breast carcinomas and adjacent breast tissues (Q35398324) (← links)
- Antigen retrieval immunohistochemistry: review and future prospects in research and diagnosis over two decades (Q35440615) (← links)
- PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance (Q35562967) (← links)
- HER2 evaluation and its impact on breast cancer treatment decisions (Q35576343) (← links)
- IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma (Q35588768) (← links)
- Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer (Q36245510) (← links)
- c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival (Q36421775) (← links)
- Mouse mammary gland is refractory to the effects of ethanol after natural lactation (Q36595433) (← links)
- Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer (Q36617556) (← links)
- Prognostic significance of HER2 gene amplification according to stage of breast cancer (Q36854475) (← links)
- Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer (Q36898399) (← links)
- FGFR1 is amplified during the progression of in situ to invasive breast carcinoma (Q36924421) (← links)
- Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial (Q36950483) (← links)
- 14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. (Q37165239) (← links)
- The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies (Q37326072) (← links)
- Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer. (Q37419479) (← links)
- Near-infrared quantum dots for HER2 localization and imaging of cancer cells (Q37641853) (← links)
- Sensitive fluorescent in situ hybridisation method for the characterisation of breast cancer cells in bone marrow aspirates (Q37641886) (← links)
- ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy (Q37662351) (← links)
- FISH detection of HER-2/neu oncogene amplification in early onset breast cancer (Q38479141) (← links)
- Evaluation of Lapatinib Powder-Entrapped Biodegradable Polymeric Microstructures Fabricated by X-Ray Lithography for a Targeted and Sustained Drug Delivery System (Q38634426) (← links)
- Analysis of promoters and expression-targeted gene therapy optimization based on doubling time and transfectability. (Q39538500) (← links)
- Biological indices in the assessment of breast cancer (Q40848953) (← links)
- Heregulins and the ErbB-2/3/4 receptors in gliomas (Q41070154) (← links)
- Targeting gene transcription: a new strategy to down-regulate c-erbB-2 expression in mammary carcinoma (Q41354221) (← links)